ABSTRACT
Prostate cancer is one of the few malignancies that includes vaccination as a treatment modality. Elements of an effective cancer vaccine should include the ability to elicit a Type I T-cell response and target multiple antigenic proteins expressed early in the disease. Using existing gene datasets encompassing normal prostate tissue and tumors with Gleason Score ≤ 6 and ≥ 8, 10 genes were identified that were upregulated and conserved in prostate cancer regardless of the aggressiveness of disease. These genes encoded proteins also expressed in prostatic intraepithelial neoplasia. Putative Class II epitopes derived from these proteins were predicted by a combination of algorithms and, using human peripheral blood, epitopes which selectively elicited IFN-γ or IL-10 dominant antigen specific cytokine secretion were determined. Th1 selective epitopes were identified for eight antigens. Epitopes from three antigens elicited Th1 dominant immunity in mice; PSMA, HPN, and AMACR. Each single antigen vaccine demonstrated significant anti-tumor activity inhibiting growth of implanted Myc-Cap cells after immunization as compared to control. Immunization with the combination of antigens, however, was superior to each alone in controlling tumor growth. When vaccination occurred simultaneously to tumor implant, multiantigen immunized mice had significantly smaller tumors than controls (p = 0.002) and a significantly improved overall survival (p = 0.0006). This multiantigen vaccine shows anti-tumor activity in a murine model of prostate cancer.
Subject(s)
Cancer Vaccines , Prostatic Neoplasms , Animals , Antigens , Disease Models, Animal , Epitopes , Epitopes, T-Lymphocyte , Humans , Male , Mice , Prostatic Neoplasms/therapy , T-LymphocytesABSTRACT
The majority of JAK2V617F-negative myeloproliferative neoplasms (MPNs) have disease-initiating frameshift mutations in calreticulin (CALR), resulting in a common carboxyl-terminal mutant fragment (CALRMUT), representing an attractive source of neoantigens for cancer vaccines. However, studies have shown that CALRMUT-specific T cells are rare in patients with CALRMUT MPN for unknown reasons. We examined class I major histocompatibility complex (MHC-I) allele frequencies in patients with CALRMUT MPN from two independent cohorts. We observed that MHC-I alleles that present CALRMUT neoepitopes with high affinity are underrepresented in patients with CALRMUT MPN. We speculated that this was due to an increased chance of immune-mediated tumor rejection by individuals expressing one of these MHC-I alleles such that the disease never clinically manifested. As a consequence of this MHC-I allele restriction, we reasoned that patients with CALRMUT MPN would not efficiently respond to a CALRMUT fragment cancer vaccine but would when immunized with a modified CALRMUT heteroclitic peptide vaccine approach. We found that heteroclitic CALRMUT peptides specifically designed for the MHC-I alleles of patients with CALRMUT MPN efficiently elicited a CALRMUT cross-reactive CD8+ T cell response in human peripheral blood samples but not to the matched weakly immunogenic CALRMUT native peptides. We corroborated this effect in vivo in mice and observed that C57BL/6J mice can mount a CD8+ T cell response to the CALRMUT fragment upon immunization with a CALRMUT heteroclitic, but not native, peptide. Together, our data emphasize the therapeutic potential of heteroclitic peptide-based cancer vaccines in patients with CALRMUT MPN.
Subject(s)
Cancer Vaccines , Myeloproliferative Disorders , Neoplasms , Animals , Calreticulin/genetics , Humans , Janus Kinase 2/genetics , Major Histocompatibility Complex , Mice , Mice, Inbred C57BL , Mutation/genetics , Myeloproliferative Disorders/genetics , Neoplasms/genetics , Peptides , Vaccines, SubunitABSTRACT
In this study, using single-cell RNA-seq, cell mass spectrometry, flow cytometry, and functional analysis, we characterized the heterogeneity of polymorphonuclear neutrophils (PMNs) in cancer. We describe three populations of PMNs in tumor-bearing mice: classical PMNs, polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs), and activated PMN-MDSCs with potent immune suppressive activity. In spleens of mice, PMN-MDSCs gradually replaced PMNs during tumor progression. Activated PMN-MDSCs were found only in tumors, where they were present at the very early stages of the disease. These populations of PMNs in mice could be separated based on the expression of CD14. In peripheral blood of cancer patients, we identified two distinct populations of PMNs with characteristics of classical PMNs and PMN-MDSCs. The gene signature of tumor PMN-MDSCs was similar to that in mouse activated PMN-MDSCs and was closely associated with negative clinical outcome in cancer patients. Thus, we provide evidence that PMN-MDSCs are a distinct population of PMNs with unique features and potential for selective targeting opportunities.
Subject(s)
Carcinoma, Lewis Lung/immunology , Carcinoma, Non-Small-Cell Lung/immunology , Lung Neoplasms/immunology , Lymphoma/immunology , Neutrophils/classification , Neutrophils/immunology , Animals , Carcinoma, Lewis Lung/pathology , Carcinoma, Non-Small-Cell Lung/blood , Case-Control Studies , Cell Line, Tumor , Disease Models, Animal , Female , Humans , Lung Neoplasms/blood , Lymphoma/pathology , Mice , Mice, Inbred C57BL , RNA-Seq , Single-Cell Analysis , TranscriptomeABSTRACT
Tumor-associated macrophages (TAM) contribute to all aspects of tumor progression. Use of CSF1R inhibitors to target TAM is therapeutically appealing, but has had very limited anti-tumor effects. Here, we have identified the mechanism that limited the effect of CSF1R targeted therapy. We demonstrated that carcinoma-associated fibroblasts (CAF) are major sources of chemokines that recruit granulocytes to tumors. CSF1 produced by tumor cells caused HDAC2-mediated downregulation of granulocyte-specific chemokine expression in CAF, which limited migration of these cells to tumors. Treatment with CSF1R inhibitors disrupted this crosstalk and triggered a profound increase in granulocyte recruitment to tumors. Combining CSF1R inhibitor with a CXCR2 antagonist blocked granulocyte infiltration of tumors and showed strong anti-tumor effects.
Subject(s)
Cancer-Associated Fibroblasts/metabolism , Monocytes/metabolism , Myeloid-Derived Suppressor Cells/metabolism , Neoplasms, Experimental/metabolism , Receptor, Macrophage Colony-Stimulating Factor/metabolism , Animals , Cancer-Associated Fibroblasts/drug effects , Cell Line, Tumor , Granulocytes/metabolism , Histone Deacetylase 2 , Humans , Imidazoles/pharmacology , Macrophages/metabolism , Mice, Inbred C57BL , Neoplasms, Experimental/drug therapy , Neoplasms, Experimental/pathology , Phenylurea Compounds/pharmacology , Pyridines/pharmacology , Receptor, Macrophage Colony-Stimulating Factor/antagonists & inhibitors , Receptors, Interleukin-8B/antagonists & inhibitors , Receptors, Interleukin-8B/metabolism , Tumor Burden/drug effectsABSTRACT
To date, anti-CTLA-4 (ipilimumab) or anti-PD-1 (nivolumab) monotherapy has not been demonstrated to be of substantial clinical benefit in patients with prostate cancer. To identify additional immune-inhibitory pathways in the prostate-tumor microenvironment, we evaluated untreated and ipilimumab-treated tumors from patients in a presurgical clinical trial. Levels of the PD-L1 and VISTA inhibitory molecules increased on independent subsets of macrophages in treated tumors. Our data suggest that VISTA represents another compensatory inhibitory pathway in prostate tumors after ipilimumab therapy.
Subject(s)
Adenocarcinoma/drug therapy , Antibodies, Monoclonal/therapeutic use , Antineoplastic Agents/therapeutic use , B7 Antigens/metabolism , B7-H1 Antigen/metabolism , Macrophages/metabolism , Prostatic Neoplasms/drug therapy , Adenocarcinoma/immunology , Adenocarcinoma/metabolism , Adult , Aged , Animals , B7 Antigens/immunology , B7-H1 Antigen/immunology , Cell Line, Tumor , Disease Models, Animal , Flow Cytometry , Fluorescent Antibody Technique , Humans , Immunohistochemistry , In Vitro Techniques , Ipilimumab , Macrophages/immunology , Male , Membrane Proteins/immunology , Membrane Proteins/metabolism , Mice , Middle Aged , Neoadjuvant Therapy , Prostatectomy , Prostatic Neoplasms/immunology , Prostatic Neoplasms/metabolism , T-Lymphocytes , Tissue Array AnalysisABSTRACT
Natural killer (NK) cells are now recognized to exhibit characteristics akin to cells of the adaptive immune system. The generation of adaptive memory is linked to epigenetic reprogramming including alterations in DNA methylation. The study herein found reproducible genome wide DNA methylation changes associated with human NK cell activation. Activation led predominately to CpG hypomethylation (81% of significant loci). Bioinformatics analysis confirmed that non-coding and gene-associated differentially methylated sites (DMS) are enriched for immune related functions (i.e., immune cell activation). Known DNA methylation-regulated immune loci were also identified in activated NK cells (e.g., TNFA, LTA, IL13, CSF2). Twenty-one loci were designated high priority and further investigated as potential markers of NK activation. BHLHE40 was identified as a viable candidate for which a droplet digital PCR assay for demethylation was developed. The assay revealed high demethylation in activated NK cells and low demethylation in naïve NK, T- and B-cells. We conclude the NK cell methylome is plastic with potential for remodeling. The differentially methylated region signature of activated NKs revealed similarities with T cell activation, but also provided unique biomarker candidates of NK activation, which could be useful in epigenome-wide association studies to interrogate the role of NK subtypes in global methylation changes associated with exposures and/or disease states.
Subject(s)
Adaptive Immunity/genetics , Basic Helix-Loop-Helix Transcription Factors/genetics , DNA Methylation/genetics , Epigenesis, Genetic/genetics , Homeodomain Proteins/genetics , Killer Cells, Natural/metabolism , B-Lymphocytes/immunology , B-Lymphocytes/metabolism , Basic Helix-Loop-Helix Transcription Factors/immunology , Blood Donors , CpG Islands/genetics , DNA/genetics , DNA/immunology , DNA Methylation/immunology , Epigenesis, Genetic/immunology , Genome-Wide Association Study , Homeodomain Proteins/immunology , Humans , Killer Cells, Natural/immunology , Lymphocyte Activation/genetics , Promoter Regions, GeneticABSTRACT
Polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) are important regulators of immune responses in cancer and have been directly implicated in promotion of tumor progression. However, the heterogeneity of these cells and lack of distinct markers hampers the progress in understanding of the biology and clinical importance of these cells. Using partial enrichment of PMN-MDSC with gradient centrifugation we determined that low density PMN-MDSC and high density neutrophils from the same cancer patients had a distinct gene profile. Most prominent changes were observed in the expression of genes associated with endoplasmic reticulum (ER) stress. Surprisingly, low-density lipoprotein (LDL) was one of the most increased regulators and its receptor oxidized LDL receptor 1 OLR1 was one of the most overexpressed genes in PMN-MDSC. Lectin-type oxidized LDL receptor 1 (LOX-1) encoded by OLR1 was practically undetectable in neutrophils in peripheral blood of healthy donors, whereas 5-15% of total neutrophils in cancer patients and 15-50% of neutrophils in tumor tissues were LOX-1+. In contrast to their LOX-1- counterparts, LOX-1+ neutrophils had gene signature, potent immune suppressive activity, up-regulation of ER stress, and other biochemical characteristics of PMN-MDSC. Moreover, induction of ER stress in neutrophils from healthy donors up-regulated LOX-1 expression and converted these cells to suppressive PMN-MDSC. Thus, we identified a specific marker of human PMN-MDSC associated with ER stress and lipid metabolism, which provides new insight to the biology and potential therapeutic targeting of these cells.
ABSTRACT
The efficacy of engaging multiple drug targets using bispecific antibodies (BsAbs) is affected by the relative cell-surface protein levels of the respective targets. In this work, the receptor density values were correlated to the in vitro activity of a BsAb (JNJ-61186372) targeting epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (c-MET). Simultaneous binding of the BsAb to both receptors was confirmed in vitro. By using controlled Fab-arm exchange, a set of BsAbs targeting EGFR and c-MET was generated to establish an accurate receptor quantitation of a panel of lung and gastric cancer cell lines expressing heterogeneous levels of EGFR and c-MET. EGFR and c-MET receptor density levels were correlated to the respective gene expression levels as well as to the respective receptor phosphorylation inhibition values. We observed a bias in BsAb binding toward the more highly expressed of the two receptors, EGFR or c-MET, which resulted in the enhanced in vitro potency of JNJ-61186372 against the less highly expressed target. On the basis of these observations, we propose an avidity model of how JNJ-61186372 engages EGFR and c-MET with potentially broad implications for bispecific drug efficacy and design.
Subject(s)
Antibodies, Bispecific/immunology , ErbB Receptors/immunology , ErbB Receptors/metabolism , Gene Expression Regulation , Molecular Targeted Therapy , Proto-Oncogene Proteins c-met/immunology , Proto-Oncogene Proteins c-met/metabolism , Antigens, Surface/chemistry , Antigens, Surface/genetics , Antigens, Surface/immunology , Antigens, Surface/metabolism , Cell Line, Tumor , ErbB Receptors/chemistry , ErbB Receptors/genetics , Humans , Immunoglobulin Fab Fragments/immunology , Models, Molecular , Mutation , Phosphorylation , Protein Multimerization , Protein Structure, Quaternary , Proto-Oncogene Proteins c-met/chemistry , Proto-Oncogene Proteins c-met/genetics , RNA, Messenger/genetics , RNA, Messenger/metabolismABSTRACT
Cytotoxic T lymphocyte antigen-4 (CTLA-4) blockade with a monoclonal antibody yields durable responses in a subset of cancer patients and has been approved by the FDA as a standard therapy for late-stage melanoma. We recently identified inducible co-stimulator (ICOS) as a crucial player in the antitumor effects of CTLA-4 blockade. We now show that concomitant CTLA-4 blockade and ICOS engagement by tumor cell vaccines engineered to express ICOS ligand enhanced antitumor immune responses in both quantity and quality and significantly improved rejection of established melanoma and prostate cancer in mice. This study provides strong support for the development of combinatorial therapies incorporating anti-CTLA-4 and ICOS engagement.
Subject(s)
CTLA-4 Antigen/antagonists & inhibitors , Immunotherapy , Inducible T-Cell Co-Stimulator Protein/metabolism , Melanoma, Experimental/drug therapy , Prostatic Neoplasms/drug therapy , Animals , Antibodies, Monoclonal/pharmacology , Antibodies, Monoclonal/therapeutic use , Antigen Presentation/drug effects , CD4-Positive T-Lymphocytes/drug effects , CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/drug effects , CD8-Positive T-Lymphocytes/immunology , CTLA-4 Antigen/metabolism , Cancer Vaccines/immunology , Cytokines/biosynthesis , Disease Models, Animal , Immunologic Memory/drug effects , Immunosuppression Therapy , Ligands , Lymphocytes, Tumor-Infiltrating/drug effects , Lymphocytes, Tumor-Infiltrating/immunology , Male , Melanoma, Experimental/immunology , Melanoma, Experimental/pathology , Mice , Prostatic Neoplasms/immunology , Prostatic Neoplasms/prevention & control , Signal Transduction/drug effects , Signal Transduction/immunology , Up-Regulation/drug effectsABSTRACT
Treatment with monoclonal antibody specific for cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), an inhibitory receptor expressed by T lymphocytes, has emerged as an effective therapy for the treatment of metastatic melanoma. Although subject to debate, current models favor a mechanism of activity involving blockade of the inhibitory activity of CTLA-4 on both effector (T eff) and regulatory (T reg) T cells, resulting in enhanced antitumor effector T cell activity capable of inducing tumor regression. We demonstrate, however, that the activity of anti-CTLA-4 antibody on the T reg cell compartment is mediated via selective depletion of T reg cells within tumor lesions. Importantly, T reg cell depletion is dependent on the presence of Fcγ receptor-expressing macrophages within the tumor microenvironment, indicating that T reg cells are depleted in trans in a context-dependent manner. Our results reveal further mechanistic insight into the activity of anti-CTLA-4-based cancer immunotherapy, and illustrate the importance of specific features of the local tumor environment on the final outcome of antibody-based immunomodulatory therapies.
Subject(s)
CTLA-4 Antigen/antagonists & inhibitors , Lymphocyte Depletion , Lymphocytes, Tumor-Infiltrating/immunology , Melanoma/immunology , Melanoma/therapy , Receptors, IgG/metabolism , T-Lymphocytes, Regulatory/immunology , Animals , Antibodies, Blocking/pharmacology , Antibodies, Blocking/therapeutic use , CD11b Antigen/metabolism , CD4 Antigens/metabolism , CD8-Positive T-Lymphocytes/drug effects , CD8-Positive T-Lymphocytes/immunology , Cell Membrane/drug effects , Cell Membrane/metabolism , Clone Cells , Fas Ligand Protein/metabolism , Granulocyte-Macrophage Colony-Stimulating Factor/therapeutic use , Lymph Nodes/drug effects , Lymph Nodes/immunology , Lymph Nodes/pathology , Lymphocyte Count , Lymphocytes, Tumor-Infiltrating/drug effects , Lymphocytes, Tumor-Infiltrating/pathology , Melanoma/pathology , Melanoma/prevention & control , Mice , Mice, Inbred C57BL , Phagocytes/drug effects , Phagocytes/immunology , Signal Transduction/drug effects , Signal Transduction/immunology , T-Lymphocytes, Regulatory/drug effects , TNF-Related Apoptosis-Inducing Ligand/metabolism , Treatment Outcome , Tumor Microenvironment/drug effects , Tumor Microenvironment/immunologyABSTRACT
Inflammation of the normally tolerant liver microenvironment precedes the development of chronic liver disease. Study of the pathogenesis of autoimmune liver diseases, such as autoimmune hepatitis (AIH), has been hampered by a lack of autochthonous chronic animal models. Through our studies of T cell costimulation, we generated transgenic mice expressing a ligand specific for the CD28 receptor, which normally shares ligands with the related inhibitory receptor CTLA-4. The mice spontaneously develop chronic inflammatory liver disease with several pathologies found in AIH, including elevated serum aminotransferases in the context of normal alkaline phosphatase and bilirubin levels, lymphocytic inflammation, focal necrosis, oval cell hyperplasia, and fibrosis. The prevalence of IFN-γ-producing CD8(+) T cells in the livers of transgenic mice suggests a role for autoimmune cytotoxicity in the chronic disease state. The CD28 ligand-specific transgenic mice will facilitate evaluation of CD8(+) T cell function in liver disease pathologies found in AIH.
Subject(s)
CD28 Antigens/immunology , Hepatitis, Autoimmune/immunology , Animals , Antigen-Presenting Cells/immunology , Antigen-Presenting Cells/metabolism , CD28 Antigens/metabolism , CD8-Positive T-Lymphocytes/immunology , Hepatitis, Autoimmune/genetics , Hepatitis, Autoimmune/pathology , Inflammation/immunology , Inflammation/metabolism , Inflammation/pathology , Interferon-gamma/immunology , Interferon-gamma/metabolism , Ligands , Male , Mice , Mice, Transgenic , Protein Binding/immunology , Single-Chain Antibodies/immunology , Single-Chain Antibodies/metabolismABSTRACT
We have previously observed that replication and nuclear location of the murine Igh locus are developmentally regulated during B cell differentiation. In non-B, B, and plasma cells, sequences near the 3' end of the Igh locus replicate early in S while upstream Vh sequences replicate late in S, and the Igh locus is located near the nuclear periphery. In fact, in MEL non-B cells, replication of a 500-kb segment containing Igh-C and flanking sequences occurs progressively later throughout S by 3' to 5' unidirectional fork movement. In contrast, in pro- and pre-B cells, the entire 3-Mb Igh locus is located away from the nuclear periphery and replicates early in S by forks progressing in both directions. In this study, using an 18-81 (pre-B) x BW5147 (T) cell fusion system in which Igh expression is extinguished, we found that in all Igh alleles, Vh sequences replicated later in S than 3' Igh sequences (similar to that detected in BW5147), but the Igh locus was situated away from the nuclear periphery (similar to that observed in 18-81). Thus, pre-B cell-derived Igh genes had changes in replication timing, but not in nuclear location, whereas T cell-derived Igh genes changed their nuclear location but not their replication timing. These data are consistent with the silencing of a pre-B cell-specific replication program in the fusion hybrid cells and independent regulation of the nuclear location of Igh loci.
Subject(s)
B-Lymphocytes/cytology , Cell Nucleus/genetics , DNA Replication , Hematopoietic Stem Cells/cytology , Hybrid Cells/cytology , Immunoglobulin Heavy Chains/biosynthesis , Immunoglobulin Heavy Chains/genetics , T-Lymphocytes/cytology , Animals , B-Lymphocytes/immunology , B-Lymphocytes/metabolism , Base Sequence , Cell Fusion , Cell Line, Tumor , Genetic Markers , Hematopoietic Stem Cells/immunology , Hematopoietic Stem Cells/metabolism , Hybrid Cells/immunology , Hybrid Cells/metabolism , Immunoglobulin Variable Region/biosynthesis , Immunoglobulin Variable Region/genetics , In Situ Hybridization, Fluorescence , Mice , T-Lymphocytes/immunology , T-Lymphocytes/metabolismABSTRACT
The murine Igh locus has a 3' regulatory region (3' RR) containing four enhancers (hs3A, hs1,2, hs3B, and hs4) at DNase I-hypersensitive sites. The 3' RR exerts long-range effects on class switch recombination (CSR) to several isotypes through its control of germ line transcription. By measuring levels of acetylated histones H3 and H4 and of dimethylated H3 (K4) with chromatin immunoprecipitation assays, we found that early in B-cell development, chromatin encompassing the enhancers of the 3' RR began to attain stepwise modifications typical of an open conformation. The hs4 enhancer was associated with active chromatin initially in pro- and pre-B cells and then together with hs3A, hs1,2, and hs3B in B and plasma cells. Histone modifications were similar in resting splenic B cells and in splenic B cells induced by lipopolysaccharide to undergo CSR. From the pro-B-cell stage onward, the approximately 11-kb region immediately downstream of hs4 displayed H3 and H4 modifications indicative of open chromatin. This region contained newly identified DNase I-hypersensitive sites and several CTCF target sites, some of which were occupied in vivo in a developmentally regulated manner. The open chromatin environment of the extended 3' RR in mature B cells was flanked by regions associated with dimethylated K9 of histone H3. Together, these data suggest that 3' RR elements are located within a specific chromatin subdomain that contains CTCF binding sites and developmentally regulated modules.
Subject(s)
3' Flanking Region/genetics , B-Lymphocytes/metabolism , Chromatin/metabolism , DNA-Binding Proteins/metabolism , Histones/metabolism , Repressor Proteins/metabolism , Acetylation/drug effects , Animals , B-Lymphocytes/immunology , Bone Marrow/immunology , Bone Marrow/metabolism , CCCTC-Binding Factor , Chromatin/genetics , Chromatin/immunology , DNA Primers/genetics , DNA-Binding Proteins/genetics , DNA-Binding Proteins/immunology , Deoxyribonuclease I/metabolism , Enhancer Elements, Genetic/genetics , Histones/genetics , Histones/immunology , Immunoglobulin Class Switching/drug effects , Immunoglobulin Class Switching/genetics , Immunoglobulin Class Switching/immunology , Lipopolysaccharides/pharmacology , Locus Control Region/genetics , Mice , Repressor Proteins/genetics , Repressor Proteins/immunology , Spleen/immunology , Spleen/metabolism , Transcription, Genetic/geneticsABSTRACT
Immunoglobulin heavy chain (Igh) locus rearrangements are controlled in part by an approximately 30 b complex 3' regulatory region located 3' of C alpha: this region contains several enhancers. We report here the comparison of the genomic sequences of the 3' regulatory region and further downstream sequences from mouse, rat, human and chimpanzee. Only short segments of homology were detected in the 3' regulatory region, and these were located in the vicinity of the known 3' enhancers. The nearest highly conserved segment is the nearest non-Igh gene, hole, which is located approximately 62 kb downstream of mouse C alpha. Analysis of murine 3' Igh sequences by single nucleotide polymorphism (SNP) and restriction fragment length polymorphism (RFLP) detected a transition region (high to low SNP or RFLP density) approximately 120 kb downstream of mouse C alpha. Although there is only limited sequence identity between rodent and primate 3' Igh regulatory regions, all of these regulatory regions contain a palindrome and locally repetitive elements. Locally repetitive elements in primates comprise blocks of "switch-like" sequences that differ from the families of inverted and tandem repeats that are present in rodents. We propose that together with enhancers, these "conserved" structural features are essential for the activity of the 3' Igh regulatory region in vivo.
Subject(s)
Genes, Immunoglobulin , 3' Untranslated Regions , Animals , Base Sequence , Chromosomes, Artificial, Bacterial/genetics , DNA/genetics , Evolution, Molecular , Gene Rearrangement, B-Lymphocyte , Genes, Regulator , Humans , Mice , Multigene Family , Pan troglodytes , Polymorphism, Restriction Fragment Length , Rats , Repetitive Sequences, Nucleic Acid , Reverse Transcriptase Polymerase Chain Reaction , Species SpecificityABSTRACT
In B cells, the Igh gene locus contains several DNase I-hypersensitive (hs) sites with enhancer activity. These include the 3' Igh enhancers, which are located downstream of the Calpha gene(s) in both mouse and human. In vivo experiments have implicated murine 3' enhancers, hs3B and/or hs4, in class switching and somatic hypermutation. We previously reported that murine hs4 was regulated by NF-kappaB, octamer binding proteins, and Pax5 (B cell-specific activator protein). In this study we report that human hs4 is regulated differently. EMSAs and Western analysis of normal B cells before and after stimulation with anti-IgM plus anti-CD40 showed the same complex binding pattern formed by NF-kappaB, Oct-1, and Oct-2 (but not by Pax5). A similar EMSA pattern was detected in mature human B cell lines (BL-2, Ramos, and HS-Sultan) and in diffuse large B cell lymphoma cell lines, although yin yang 1 protein (YY1) binding was also observed. We have confirmed the in vivo association of these transcription factors with hs4 in B cells by chromatin immunoprecipitation assays. The diffuse large B cell lymphoma cell lines had a distinctive slow-migrating complex containing YY1 associated with Rel-B. We have confirmed by endogenous coimmunoprecipitation an association of YY1 with Rel-B, but not with other NF-kappaB family members. Transient transfection assays showed robust hs4 enhancer activity in the mature B cell lines, which was dependent on synergistic interactions between NF-kappaB and octamer binding proteins. In addition, human hs4 enhancer activity required Oct-2 and correlated with expression of Oct coactivator from B cells (OCA-B).
Subject(s)
3' Untranslated Regions/immunology , B-Lymphocytes/immunology , DNA-Binding Proteins/physiology , Enhancer Elements, Genetic/immunology , Immunoglobulin Heavy Chains/genetics , NF-kappa B/physiology , Nuclear Proteins , Trans-Activators/physiology , Transcription Factors/physiology , Animals , B-Lymphocytes/chemistry , B-Lymphocytes/metabolism , Cell Cycle Proteins , Chromatin/metabolism , DNA-Binding Proteins/metabolism , Electrophoretic Mobility Shift Assay , Host Cell Factor C1 , Humans , Immunoglobulin Heavy Chains/metabolism , Mice , NF-kappa B/metabolism , Octamer Transcription Factor-1 , Octamer Transcription Factor-2 , PAX5 Transcription Factor , Precipitin Tests , Protein Binding/genetics , Protein Binding/immunology , Proteins/isolation & purification , Proteins/metabolism , Proto-Oncogene Proteins/isolation & purification , Trans-Activators/metabolism , Transcription Factor RelB , Transcription Factors/isolation & purification , Transcription Factors/metabolism , TransfectionABSTRACT
In yeast, the transcriptional adaptor yeast Ada2 (yAda2) is a part of the multicomponent SAGA complex, which possesses histone acetyltransferase activity through action of the yGcn5 catalytic enzyme. yAda2, among several SAGA proteins, serves to recruit SAGA to genes via interactions with promoter-bound transcription factors. Here we report identification of a new human Ada2 homologue, hAda2beta. Ada2beta differs both biochemically and functionally from the previously characterized hAda2alpha, which is a stable component of the human PCAF (human Gcn5 homologue) acetylase complex. Ada2beta, relative to Ada2alpha, interacted selectively, although not stably, with the Gcn5-containing histone acetylation complex TFTC/STAGA. In addition, Ada2beta interacted with Baf57 (a component of the human Swi/Snf complex) in a yeast two-hybrid screen and associated with human Swi/Snf in vitro. In functional assays, hAda2beta (but not Ada2alpha), working in concert with Gcn5 (but not PCAF) or Brg1 (the catalytic component of hSwi/Snf complex), increased transcription via the B-cell-specific transcription factor Pax5/BSAP. These findings support the view that Gcn5 and PCAF have distinct roles in vivo and suggest a new mechanism of coactivator function, in which a single adaptor protein (Ada2beta) can coordinate targeting of both histone acetylation and chromatin remodeling activities.
Subject(s)
Acetyltransferases/metabolism , Carrier Proteins/metabolism , Nuclear Proteins/metabolism , Trans-Activators/metabolism , Transcription Factors/metabolism , Transcription, Genetic , Adaptor Proteins, Signal Transducing , Amino Acid Sequence , Antigens, CD19/genetics , Antigens, CD19/metabolism , B-Lymphocytes/metabolism , Base Sequence , Carrier Proteins/chemistry , Cell Line , DNA Helicases , DNA-Binding Proteins/metabolism , Glutathione Transferase/metabolism , HeLa Cells , Humans , Molecular Sequence Data , PAX5 Transcription Factor , Promoter Regions, Genetic , Protein Structure, Tertiary , Recombinant Fusion Proteins/metabolism , Sequence Homology, Amino Acid , Transcription Factors/chemistry , Transcriptional ActivationABSTRACT
Pax5 (BSAP) is essential for B cell development and acts both as a transcriptional activator and a repressor. Using a yeast two-hybrid assay to identify potential coregulators of Pax5, we identified Daxx, a protein that is highly conserved, ubiquitously expressed, and essential for embryonic mouse development. The interaction between Pax5 and Daxx involves the partial homeodomain of Pax5 and the C-terminal fragment of Daxx. A component of promyelocytic leukemia protein nuclear bodies, Daxx has been implicated in apoptosis and characterized as a transcriptional corepressor. Upon transient transfection assay of Daxx in B cells expressing endogenous Daxx and Pax5, we observed not only transcriptional corepression but also, unexpectedly, coactivation in M12.4.1 and A20 mouse B cell lines. Pax5 domains required for coactivation were identified using 293T cells. Coactivation apparently involves recruitment of the CREB binding protein (CBP), because we precipitated complexes containing Pax5, Daxx, and CBP in B cell lines. These data suggest that Daxx can affect Pax5's roles as an activator or repressor in B cells and describe a role for Daxx as a transcriptional coactivator.